Results 151 to 160 of about 3,929 (296)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial. [PDF]

JCO Oncol Adv
Ivory JM, Gunn HJ, Wheeler SB, Drier S, Paskett E, Naughton M, McCue S, Wills R, Williams K, Chow S, Charlot M, Reeder-Hayes KE.   +11 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Visionary Leadership in Cancer Care: An Interview With Professor Timothy J. Eberlein. [PDF]

Ann Gastroenterol Surg
Shirabe K, Mimori K, Mori M, Kitagawa Y.
europepmc   +1 more source

Audit Quality and the Accrual Anomaly

Korea International Accounting Review, 2010
null Kim, Tae-Wan, null Kwon,Young-Do
openaire   +1 more source

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug‐Resistant Tuberculosis

Clinical Pharmacology &Therapeutics, EarlyView.
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell, Antonio Lombardi, William Brumskine, Lali Mikiashvili, Kim Boekelheide, Joanna Moreira, Alda Holsta, Matthew Betteridge, Lindsay Thompson, Angela Crook, Paul Bruinenberg, Maria Beumont, Eugene Sun, Francesca Conradie   +13 more
wiley   +1 more source

Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005. [PDF]

J Magn Reson Imaging
Alley S, Tonneau M, Olivié D, Tempany-Afdhal CM, Choyke PL, Turkbey IB, van der Heide UA, Ellis RJ, Kadoury S, Boike TP, Pennington JD, Frazier A, Lawton CAF, Leong N, Mihai AM, Morgan SC, Solanki AA, Michalski JM, Feng FY, Sandler HM, Menard C.   +20 more
europepmc   +1 more source

The Covid-19 outbreak, corporate financial distress and earnings management. [PDF]

Int Rev Financ Anal, 2023
Aljughaiman AA, Nguyen TH, Trinh VQ, Du A.   +3 more
europepmc   +1 more source

Evidence on (the lack of) audit-quality differentiation in the private client segment of the Belgian audit market?. [PDF]

Auditor size is used as audit-quality proxy. Prior evidence on audit-quality differentiation between big 6 and non-big 6 auditors in the private client segment of the Belgian audit market is mixed. In this paper we investigate whether these mixed results
Willekens, Marleen, Vander Bauwhede, Heidi   +1 more
core  

When Sustainability Reporting Becomes a Strategy: The Impact of Financial Performance and Institutional Pressures From EU Sustainability Reporting Regulations on ESG Decoupling

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Mitigating environmental, social, and governance (ESG) decoupling is essential to advancing reliable sustainability disclosure and ensuring that ESG reporting fulfills its intended purpose. This study aims to provide critical insights into the organizational and contextual elements that could intensify or diminish ESG decoupling. Using a multi‐
Catarina Cepêda, Albertina Paula Monteiro, Cristina Aibar‐Guzmán   +2 more
wiley   +1 more source